KR20220034061A - 중수소화 또는 부분적 중수소화 n,n-다이메틸트립타민 화합물을 포함하는 치료 조성물 - Google Patents

중수소화 또는 부분적 중수소화 n,n-다이메틸트립타민 화합물을 포함하는 치료 조성물 Download PDF

Info

Publication number
KR20220034061A
KR20220034061A KR1020217043410A KR20217043410A KR20220034061A KR 20220034061 A KR20220034061 A KR 20220034061A KR 1020217043410 A KR1020217043410 A KR 1020217043410A KR 20217043410 A KR20217043410 A KR 20217043410A KR 20220034061 A KR20220034061 A KR 20220034061A
Authority
KR
South Korea
Prior art keywords
dimethyltryptamine
composition
compound
dideutero
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217043410A
Other languages
English (en)
Korean (ko)
Inventor
피터 랜즈
젤라 조엘
티파니 벤웨이
Original Assignee
스몰 파마 엘티디
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스몰 파마 엘티디 filed Critical 스몰 파마 엘티디
Priority to KR1020247030292A priority Critical patent/KR20240142567A/ko
Publication of KR20220034061A publication Critical patent/KR20220034061A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020217043410A 2019-06-03 2020-06-02 중수소화 또는 부분적 중수소화 n,n-다이메틸트립타민 화합물을 포함하는 치료 조성물 Ceased KR20220034061A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247030292A KR20240142567A (ko) 2019-06-03 2020-06-02 중수소화 또는 부분적 중수소화 n,n-다이메틸트립타민 화합물을 포함하는 치료 조성물

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1907871.6 2019-06-03
GBGB1907871.6A GB201907871D0 (en) 2019-06-03 2019-06-03 Therapeutic compositions
PCT/EP2020/065244 WO2020245133A1 (en) 2019-06-03 2020-06-02 Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247030292A Division KR20240142567A (ko) 2019-06-03 2020-06-02 중수소화 또는 부분적 중수소화 n,n-다이메틸트립타민 화합물을 포함하는 치료 조성물

Publications (1)

Publication Number Publication Date
KR20220034061A true KR20220034061A (ko) 2022-03-17

Family

ID=67385960

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020217043410A Ceased KR20220034061A (ko) 2019-06-03 2020-06-02 중수소화 또는 부분적 중수소화 n,n-다이메틸트립타민 화합물을 포함하는 치료 조성물
KR1020247030292A Ceased KR20240142567A (ko) 2019-06-03 2020-06-02 중수소화 또는 부분적 중수소화 n,n-다이메틸트립타민 화합물을 포함하는 치료 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020247030292A Ceased KR20240142567A (ko) 2019-06-03 2020-06-02 중수소화 또는 부분적 중수소화 n,n-다이메틸트립타민 화합물을 포함하는 치료 조성물

Country Status (20)

Country Link
US (3) US11771681B2 (https=)
EP (2) EP3826632B1 (https=)
JP (1) JP7523474B2 (https=)
KR (2) KR20220034061A (https=)
CN (1) CN114096246B (https=)
AU (1) AU2020286709B2 (https=)
BR (1) BR112021024333A2 (https=)
CA (2) CA3142290C (https=)
DK (1) DK3826632T3 (https=)
EA (1) EA202193338A1 (https=)
ES (1) ES2922101T3 (https=)
GB (4) GB201907871D0 (https=)
HR (1) HRP20220837T8 (https=)
HU (1) HUE059439T2 (https=)
IL (1) IL288617B2 (https=)
MX (1) MX2021014728A (https=)
PL (1) PL3826632T3 (https=)
PT (1) PT3826632T (https=)
TW (1) TWI860478B (https=)
WO (1) WO2020245133A1 (https=)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201907871D0 (en) 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
KR20220082092A (ko) 2019-11-07 2022-06-16 스몰 파마 엘티디 화합물
KR20220137081A (ko) 2020-02-04 2022-10-11 마인드셋 파마 인크. Cns 장애의 치료를 위한 세로토닌성 사이키델릭 작용제로서의 실로신 유도체
BR112022015379A2 (pt) 2020-02-04 2022-09-27 Mindset Pharma Inc Derivados de 3-pirrolidino-indol como agentes psicodélicos serotonérgicos para o tratamento de distúrbios do snc
WO2021226416A1 (en) 2020-05-08 2021-11-11 Psilera Inc. Novel compositions of matter and pharmaceutical compositions
US12240813B2 (en) 2020-05-19 2025-03-04 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
MX2022014900A (es) * 2020-06-02 2023-03-27 Small Pharma Ltd Composiciones terapeuticas que comprenden compuestos n,n-dimetiltriptamina deuterada o parcialmente deuterada.
GB2605144A (en) * 2021-03-22 2022-09-28 Small Pharma Ltd Deuterated compounds
US12042564B2 (en) 2020-06-02 2024-07-23 Cybin Uk Ltd Therapeutic solid dosage forms
EP3902541B1 (en) * 2020-06-02 2022-09-14 Small Pharma Ltd Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
US11773062B2 (en) 2021-03-22 2023-10-03 Small Pharma Ltd Deuterated compounds
AU2021328671A1 (en) 2020-08-18 2023-02-16 Cybin Irl Limited Phenethylamine derivatives, compositions, and methods of use
JP7422474B2 (ja) * 2020-08-28 2024-01-26 サイビン ユーケー リミテッド 注射用製剤
US11406619B2 (en) 2020-08-28 2022-08-09 Small Pharma Ltd Injectable formulations
US11660289B2 (en) 2020-12-01 2023-05-30 Small Pharma Ltd. Deuterated or partially deuterated N,N-dimethyltryptamine compounds
US12521370B2 (en) 2020-12-01 2026-01-13 Cybin Uk Ltd Inhalable formulations
EP4031529B1 (en) 2020-12-01 2023-09-27 Small Pharma Ltd Deuterated or partially deuterated n,n-dimethyltryptamine compounds
EP4255422A4 (en) * 2020-12-03 2024-12-18 Mydecine Innovations Group Inc. NEW PSILOCIN ANALOGUE COMPOSITIONS AND METHODS OF THEIR SYNTHESIS
AU2022229037A1 (en) * 2021-03-02 2023-09-28 Mindset Pharma Inc. Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto
JP2024517738A (ja) * 2021-04-26 2024-04-23 アタイ セラピューティクス， インコーポレイテッド 新規のｎ，ｎ－ジメチルトリプタミン組成物および方法
US20230136824A1 (en) 2021-04-26 2023-05-04 ATAI Life Sciences AG N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof
CA3217559A1 (en) * 2021-05-05 2022-11-10 Kamaluddin Abdur-Rashid Catalytic tryptamine processes and precursors
KR20240009433A (ko) * 2021-05-17 2024-01-22 사이빈 아이알엘 리미티드 실로시빈의 제형
CA3218110A1 (en) * 2021-05-25 2022-12-01 Majed Fawaz New n,n-dimethyltryptamine salts and crystalline salt forms
US20240286998A1 (en) * 2021-06-02 2024-08-29 Saint Joseph's University Fluorinated tryptamine compounds, analogues thereof, and methods using same
AU2022287974A1 (en) 2021-06-09 2024-01-04 Atai Therapeutics, Inc. Novel prodrugs and conjugates of dimethyltryptamine
KR20240058859A (ko) 2021-08-12 2024-05-03 쿨레온 엘엘씨 환각성 및 비환각성 세로토닌 수용체 작용제 및 이의 제조 및 사용 방법
EP4392028A4 (en) * 2021-08-23 2025-09-24 Alexander Shulgin Res Institute Inc DEUTERATED EMPATHOGENS
EP4392027A4 (en) 2021-08-23 2025-07-23 Alexander Shulgin Res Institute Inc FLUORINATED EMPATHOGENS
US11697638B2 (en) 2021-09-08 2023-07-11 Small Pharma Ltd 5-methoxy-N,N-dimethyltryptamine crystalline forms
EP4159201A1 (en) 2021-09-30 2023-04-05 Biomind Labs Inc Encapsulated microparticles and nanoparticles of dimethyltriptamines
EP4159192A1 (en) 2021-09-30 2023-04-05 Biomind Labs Inc Dimethyltriptamine-based nasal spray for the personalised treatment of neurological and psychiatric disorders
WO2023076135A1 (en) * 2021-10-29 2023-05-04 Psilera Inc. N,n-dimethyltryptamine (dmt) crystalline products and methods of making the same
US12318477B2 (en) 2021-11-18 2025-06-03 Cybin Uk Ltd Injectable and inhalable formulations
EP4433049A1 (en) 2021-11-18 2024-09-25 Cybin UK Ltd Injectable and inhalable formulations
WO2023129956A2 (en) 2021-12-30 2023-07-06 ATAI Life Sciences AG Dimethyltryptamine analogues as nitric oxide delivery drugs
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
CA3246274A1 (en) * 2022-03-31 2023-10-05 Cybin Irl Limited METHODS OF ADMINISTRATING PSYCHEDELIC MEDICINES BY INHALATION AND SYSTEMS FOR IMPLEMENTING THESE METHODS
AU2023269880A1 (en) 2022-05-10 2024-01-18 Mydecine Innovations Group Inc. Novel psilocin prodrug compounds and methods of synthesizing the same
WO2024108195A1 (en) 2022-11-17 2024-05-23 Remedi, Inc. Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use
CN121194779A (zh) 2023-03-31 2025-12-23 赛本英国有限公司 包含单胺抗抑郁剂和短效致幻剂的组合
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same
WO2026013174A1 (en) 2024-07-10 2026-01-15 Cybin Uk Ltd Pharmaceutical compositions comprising deuterated n,n-dimethyltryptamine

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4336378A (en) 1980-04-10 1982-06-22 Sandoz, Inc. Isoxazolyl indolamines
AU1928892A (en) 1991-06-21 1993-01-25 Smithkline Beecham Plc Tryptamine analogues, their synthesis and their use as 5-ht1-like or 5-ht2 receptor agonists
US6376531B1 (en) 1998-11-13 2002-04-23 Rupert Charles Bell Method of treatment using deuterium compounds
EP1292282A2 (en) 2000-06-16 2003-03-19 RTP Pharma Inc. Improved injectable dispersions of propofol
ITRM20010356A1 (it) 2001-06-21 2002-12-23 Sigma Tau Ind Farmaceuti "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina.
WO2004085392A1 (en) 2003-03-25 2004-10-07 Faust Pharmaceuticals Melatonin derivatives and their use for treating neurological dysfunctions
CA2666149A1 (en) 2006-10-19 2008-04-24 Auspex Pharmaceuticals, Inc. Substituted indoles
WO2008071455A1 (en) 2006-12-15 2008-06-19 Bayer Schering Pharma Aktiengesellschaft Bicyclic acyltryptophanols
CZ302424B6 (cs) 2007-06-13 2011-05-11 Zentiva, A. S. Zpusob prípravy almotriptanu o vysoké cistote
US20090076121A1 (en) 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched sumatriptan
EP2209380A4 (en) 2007-10-09 2011-09-14 Mark T Hamann METHOD OF USE OF COMPOSITIONS WITH ANTIDEPRESSIVE EFFICACY, MOOD EFFICACY AND OTHER NEUROLOGICAL EFFECTIVENESS AND COMPOSITIONS THEREOF
US20100069399A1 (en) * 2008-09-15 2010-03-18 Auspex Pharmaceutical, Inc. Arylpiperazine modulators of d2 receptors, 5-ht1a receptors, and/or 5-ht2a receptors
JP6367545B2 (ja) 2013-12-17 2018-08-01 コンサート ファーマシューティカルズ インコーポレイテッド ルキソリチニブの重水素化誘導体
EP3519816A4 (en) 2016-09-29 2020-05-06 The Regents of the University of California CONNECTIONS FOR INCREASING NEURONAL PLASTICITY
CA3052974A1 (en) 2017-02-09 2018-08-16 CaaMTech, LLC Compositions and methods comprising a psilocybin derivative
US20200147038A1 (en) 2017-04-20 2020-05-14 Eleusis Benefit Corporation, Pbc Assessing and treating psychedelic-responsive subjects
CN109251151A (zh) * 2017-07-12 2019-01-22 北京广为医药科技有限公司 N-(2-(取代-萘-1-基)乙基)取代酰胺类化合物、其制备及其用途
MA50786A (fr) * 2017-10-26 2022-04-27 Blumentech S L Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques
WO2019089902A1 (en) 2017-11-01 2019-05-09 Drexel University Compounds, compositions, and methods for treating diseases
HUE069534T2 (hu) 2019-02-22 2025-03-28 Gh Res Ireland Limited 5-Metoxi-N,N-dimetiltriptamint (5-MeO-DMT) tartalmazó készítmény mentális rendellenességek kezelésében történõ alkalmazásra
FI4349407T3 (fi) 2019-02-22 2025-06-02 Gh Res Ireland Limited 5-metoksi-n,n-dimetyylitryptamiini (5-meo-dmt) vaikean masennuksen hoitoon
MX2021010198A (es) 2019-02-27 2021-09-21 Univ California Indoles n-sustituidos y otros heterociclos para el tratamiento de trastornos cerebrales.
KR102946120B1 (ko) 2019-02-27 2026-03-30 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 뇌 장애를 치료하기 위한 아제피노-인돌 및 다른 헤테로사이클
GB201907871D0 (en) 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
KR20220082092A (ko) 2019-11-07 2022-06-16 스몰 파마 엘티디 화합물
KR20220137081A (ko) 2020-02-04 2022-10-11 마인드셋 파마 인크. Cns 장애의 치료를 위한 세로토닌성 사이키델릭 작용제로서의 실로신 유도체
US12240813B2 (en) 2020-05-19 2025-03-04 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
WO2021234608A1 (en) 2020-05-19 2021-11-25 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
US12042564B2 (en) 2020-06-02 2024-07-23 Cybin Uk Ltd Therapeutic solid dosage forms
US11773062B2 (en) 2021-03-22 2023-10-03 Small Pharma Ltd Deuterated compounds
EP3902541B1 (en) 2020-06-02 2022-09-14 Small Pharma Ltd Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
GB202008961D0 (en) 2020-06-12 2020-07-29 Beckley Psytech Ltd Pharmaceutical composition
EP4192451A4 (en) 2020-08-05 2024-08-14 Universitätsspital Basel METHOD OF ADMINISTERING INTRAVENOUS DMT FOR DMT-ASSISTED PSYCHOTHERAPY
US20220062237A1 (en) 2020-08-28 2022-03-03 Small Pharma Ltd Injectable formulation
US11406619B2 (en) 2020-08-28 2022-08-09 Small Pharma Ltd Injectable formulations
JP7422474B2 (ja) 2020-08-28 2024-01-26 サイビン ユーケー リミテッド 注射用製剤
EP4221682A2 (en) 2020-10-02 2023-08-09 Cybin IRL Limited Methods for delivery of psychedelic medications by inhalation and systems for performing the methods
US11000534B1 (en) 2020-10-08 2021-05-11 Lennham Pharmaceuticals, Inc. Deuterated derivatives of psilocybin and uses thereof
EP4031529B1 (en) 2020-12-01 2023-09-27 Small Pharma Ltd Deuterated or partially deuterated n,n-dimethyltryptamine compounds
US11660289B2 (en) 2020-12-01 2023-05-30 Small Pharma Ltd. Deuterated or partially deuterated N,N-dimethyltryptamine compounds
US12521370B2 (en) 2020-12-01 2026-01-13 Cybin Uk Ltd Inhalable formulations
US11697638B2 (en) 2021-09-08 2023-07-11 Small Pharma Ltd 5-methoxy-N,N-dimethyltryptamine crystalline forms
US12318477B2 (en) 2021-11-18 2025-06-03 Cybin Uk Ltd Injectable and inhalable formulations

Also Published As

Publication number Publication date
HRP20220837T1 (hr) 2022-10-14
WO2020245133A1 (en) 2020-12-10
US20220168275A1 (en) 2022-06-02
GB202107702D0 (en) 2021-07-14
MX2021014728A (es) 2022-03-11
JP2022535093A (ja) 2022-08-04
HRP20220837T8 (hr) 2023-02-03
US11771681B2 (en) 2023-10-03
GB2592822B (en) 2023-07-05
EP4062910A1 (en) 2022-09-28
GB2586940A (en) 2021-03-10
GB2586940B (en) 2023-07-05
NZ783166A (en) 2025-06-27
CA3104072C (en) 2022-07-19
GB201907871D0 (en) 2019-07-17
GB2585978B (en) 2021-07-14
TWI860478B (zh) 2024-11-01
TW202210075A (zh) 2022-03-16
US20200390746A1 (en) 2020-12-17
CN114096246A (zh) 2022-02-25
CA3142290A1 (en) 2020-12-10
GB202008303D0 (en) 2020-07-15
HUE059439T2 (hu) 2022-11-28
IL288617B1 (en) 2024-10-01
US20240374565A1 (en) 2024-11-14
JP7523474B2 (ja) 2024-07-26
EP3826632A1 (en) 2021-06-02
ES2922101T3 (es) 2022-09-08
GB2592822A (en) 2021-09-08
PL3826632T3 (pl) 2022-08-01
GB202100807D0 (en) 2021-03-10
EA202193338A1 (ru) 2022-03-02
EP4062910B1 (en) 2025-12-24
CN114096246B (zh) 2024-11-22
CA3104072A1 (en) 2021-06-28
CA3142290C (en) 2025-03-04
EP3826632B1 (en) 2022-05-18
PT3826632T (pt) 2022-07-11
US12076311B2 (en) 2024-09-03
AU2020286709B2 (en) 2024-05-09
BR112021024333A2 (pt) 2022-02-08
IL288617A (en) 2022-02-01
DK3826632T3 (da) 2022-07-11
KR20240142567A (ko) 2024-09-30
IL288617B2 (en) 2025-02-01
AU2020286709A1 (en) 2022-01-06
GB2585978A (en) 2021-01-27

Similar Documents

Publication Publication Date Title
KR20220034061A (ko) 중수소화 또는 부분적 중수소화 n,n-다이메틸트립타민 화합물을 포함하는 치료 조성물
JP7579888B2 (ja) 治療用固形製剤
US20220169606A1 (en) Compositions and compounds for bioanalysis
KR102589605B1 (ko) 중수소화 또는 부분 중수소화 n,n-디메틸트립타민 화합물을 포함하는 치료용 조성물
HK40060891A (en) Therapeutic compositions
HK40081622A (en) Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
HK40045846A (en) Therapeutic compositions
EA046951B1 (ru) Терапевтические композиции, включающие дейтерированные или частично дейтерированные соединения n,n-диметилтриптамина
US20240342101A1 (en) Therapeutic solid dosage forms
HK40064531A (en) Therapeutic solid dosage forms
HK40065709A (en) Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0601 Decision of rejection after re-examination

St.27 status event code: N-2-6-B10-B17-rex-PX0601

X601 Decision of rejection after re-examination
T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

J201 Request for trial against refusal decision
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

PJ1301 Trial decision

St.27 status event code: A-3-3-V10-V15-crt-PJ1301

Decision date: 20251125

Appeal event data comment text: Appeal Kind Category : Appeal against decision to decline refusal, Appeal Ground Text : 2021 7043410

Appeal request date: 20240910

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2024101001975

V15 Decision substituted

Free format text: ST27 STATUS EVENT CODE: A-3-3-V10-V15-CRT-PJ1301 (AS PROVIDED BY THE NATIONAL OFFICE); DECISION IDENTIFIER: 2024101001975; DECISION AUTHORITY: OFFICE APPEAL BOARD, APPEAL KIND CATEGORY : APPEAL AGAINST DECISION TO DECLINE REFUSAL

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000